Empagliflozin Decreased Proteinuria in Patients with Glomerulonephritis without Diabetes: A Randomized Clinical Trial
Objective: Empagliflozin (EMPA) is a new class of hypoglycemic drugs acting as a sodium glucose co-transporter 2 inhibi tor. In addition to reducing blood sugar, cardiovascular complications, and mortality rate, EMPA also has kidney protective properties (such as reducing proteinuria, progression o...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Turkish Society of Nephrology
2025-10-01
|
| coleção: | Turkish Journal of Nephrology |
| Assuntos: | |
| Acesso em linha: | https://turkjnephrol.org/index.php/pub/article/view/1671 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|